deferoxamine has been researched along with Muscular Dystrophy, Duchenne in 2 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Muscular Dystrophy, Duchenne: An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Based on evidence that excess iron may increase oxidative stress and contribute to the inflammatory response, we investigated whether deferoxamine (DFX), a potent iron chelating agent, reduces oxidative stress and inflammation in the diaphragm (DIA) muscle of mdx mice (an experimental model of DMD)." | 3.81 | Reduction of Oxidative Damage and Inflammatory Response in the Diaphragm Muscle of mdx Mice Using Iron Chelator Deferoxamine. ( de Almeida Hermes, T; de Burgos, RR; de Faria, FM; Macedo, AB; Minatel, E; Moraes, LH, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moraes, LH | 2 |
| Bollineli, RC | 1 |
| Mizobuti, DS | 1 |
| Silveira, Ldos R | 1 |
| Marques, MJ | 1 |
| Minatel, E | 2 |
| de Burgos, RR | 1 |
| Macedo, AB | 1 |
| de Almeida Hermes, T | 1 |
| de Faria, FM | 1 |
2 other studies available for deferoxamine and Muscular Dystrophy, Duchenne
| Article | Year |
|---|---|
Effect of N-acetylcysteine plus deferoxamine on oxidative stress and inflammation in dystrophic muscle cells.
Topics: Acetylcysteine; Aldehydes; Animals; Cells, Cultured; Deferoxamine; Hydrogen Peroxide; Inflammation; | 2015 |
Reduction of Oxidative Damage and Inflammatory Response in the Diaphragm Muscle of mdx Mice Using Iron Chelator Deferoxamine.
Topics: Animals; Blotting, Western; Body Weight; Deferoxamine; Diaphragm; Female; Inflammation; Injections, | 2015 |